New potential treatment modalities for disseminated prostatic cancer.
The authors consider treatments that are applicable to disseminated prostatic cancer. Several types of potential developments in systemic therapy for prostatic cancer are considered: new hormonal agents, new cytotoxic agents, modulation of the antitumor efficacy or toxicity or both of standard agents, biologic response modifiers, drug delivery systems, and systems for prediction of response.
D000726:Androgen Antagonists / Q000627:therapeutic use; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002277:Carcinoma / Q000628:therapy*; D002369:Castration; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000031:analogs & derivatives; D005467:Floxuridine / Q000627:therapeutic use; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D007372:Interferons / Q000627:therapeutic use; D007536:Isomerism; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use; D009279:Naphthacenes / Q000627:therapeutic use; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000628:therapy*; D013951:Thymus Hormones / Q000627:therapeutic use; D014410:Tumor Stem Cell Assay
D000726:Androgen Antagonists; D000903:Antibiotics, Antineoplastic; D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D006728:Hormones; D009279:Naphthacenes; D009607:Nitrosourea Compounds; D009944:Organoplatinum Compounds; D013951:Thymus Hormones; D005467:Floxuridine; D003520:Cyclophosphamide; D007372:Interferons; C025034:doxifluridine; D008727:Methotrexate